Bio-Matrix Scientific Group's Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I SAN DIEGO, CA--(Marketwired - Oct 31, 2013) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) announced today that Regen BioPharma Inc. (a subsidiary of BMSN) is initiating the production of clinical-grade HemaXellerate I using the Good Manufacturing Practices (GMP)-compliant contract manufacturer Cook General Biotechnology. The initial batches will be utilized for completing preclinical experiments requested by the FDA for IND # #15376 for a clinical trial using HemaXellerate I as a therapeutic for treatment resistant aplastic anemia. HemaXellerate I is a personalized stem cell treatment that utilizes fat derived cells to inhibit the biological processes responsible for aplastic anemia.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.